Sprycel holds hope for treating Src dependent ovarian cancer

Links shared publicly online about this topic.

1,611
total visits

Sprycel holds hope for treating Src dependent ovarian cancer

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

View full resource at news-medical.net

Tags: Cancer, Leukemia, Ovarian Cancer, Drug, Women's Health, FDA